KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precigen (PGEN) Common Equity (2016 - 2025)

Precigen (PGEN) has disclosed Common Equity for 13 consecutive years, with $41.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Common Equity fell 24.39% to $41.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $41.9 million, a 24.39% decrease, with the full-year FY2024 number at $38.5 million, down 67.5% from a year prior.
  • Common Equity was $41.9 million for Q3 2025 at Precigen, up from -$36.8 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $184.1 million in Q1 2023 to a low of -$36.8 million in Q2 2025.
  • A 5-year average of $95.4 million and a median of $107.3 million in 2021 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: skyrocketed 221.34% in 2021, then plummeted 185.2% in 2025.
  • Precigen's Common Equity stood at $107.3 million in 2021, then increased by 17.62% to $126.3 million in 2022, then decreased by 6.15% to $118.5 million in 2023, then plummeted by 67.5% to $38.5 million in 2024, then rose by 8.71% to $41.9 million in 2025.
  • Per Business Quant, the three most recent readings for PGEN's Common Equity are $41.9 million (Q3 2025), -$36.8 million (Q2 2025), and -$14.1 million (Q1 2025).